If this is a forwarded email, subscribe now to receive future updates on this topic. |
|---|
You are subscribed to one or more CDC code set email subscription services. Subscription links are available on each of the pages below. Vaccine Code Set Update Publication Date: July 31, 2024
The individual filenames included in this distribution contain the publication date (20240731) Release Notes: This release includes updates to all regular vaccine code set files plus the CVX to Vaccine Information Statement (VIS) file. General Note Regarding this Release: Codes with “Last Update” dates after June 12, 2024, and before July 30, 2024, reflect the changes and additions in this release. This release includes the following code set updates: 1. New Pneumococcal Conjugate 21 Valent Vaccine (PCV 21)
2. Seasonal Influenza Vaccines - New Trivalent Influenza Vaccines for 2024/2025 Season
- Retired Quadrivalent Influenza Vaccines for 2023/2024 Season
3. Other Code Updates - New NDCs Added
- Updated RABAVERT MVX Code and Product Tradename Crosswalk
- CPT to CVX Code Map Updates
- Other NDC Updates
4. New NDC Consolidated Crosswalk Table Added to CDC’s IIS Data Code Sets Website In addition to the code changes above, the following updates have been made to CDC’s IIS Data Code Sets website’s Seasonal Influenza Codes and Crosswalk tables. You can access here Fall Season Respiratory Vaccine Codes | CDC. - Table Removed: “Preview of the Trivalent Influenza Vaccine Codes for Season 2024/2025”
- Table Updated Table: “Influenza Vaccines for Season 2024/2025 (Northern Hemisphere)” now reflects the updated trivalent vaccines
Vaccine Code Set Updates – Details 1. New Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) Merck has introduced a new PCV 21 vaccine, CAPVAXIVE. The following information has been added to the code sets. Proprietary Name | Sale Labeler | Sale NDC10
Sale NDC11 | SalePackForm | Use NDC10
Use NDC11 | UsePackForm |
|---|
CAPVAXIVE | Merck Sharp & Dohme LLC | 0006-4347-01
00006-4347-01 | CARTON, 1 SYRINGE | 0006-4347-99
00006-4347-99 | SYRINGE, 0.5mL |
|---|
0006-4347-02
00006-4347-02 | CARTON, 10 SYRINGE | 0006-4347-99
00006-4347-99 | SYRINGE, 0.5mL |
|---|
- The above NDCs are associated to the following vaccine codes. The CVX and CPT codes are new:
MVX Code | MVX Manufacturer | CVX Code | CVX Short Description | CVX Long Description | CPT | CPT Short Description | CPT Long Description |
|---|
MSD | Merck and Co., Inc. | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free | 90684 | PCV21 VACCINE IM | Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use |
|---|
In addition to the above codes, CDC has added a new product table record for CAPVAXIVE which is mapped to CVX 327 and MVX MSD.
Important Note: Until an updated VIS statement is available, the currently available VIS for PCV should be utilized. Accordingly, the CVX to VIS map has been updated to map CVX 327 to the current edition of the PCV VIS Document: ID 253088698300049311230512, “Pneumococcal Conjugate Vaccine (PCV13_PCV15_PCV20) VIS”. 2. Seasonal Influenza Vaccines - New Trivalent Influenza Vaccines for 2024/2025 Season
Influenza vaccines for the upcoming 2024/2025 season will no longer be quadrivalent. Three strains have been approved for the coming year and thus the new seasonal vaccines are trivalent. In the May 26th vaccine code set release, CDC updated the existing trivalent CVX codes, added one new CVX code and added new trivalent product tradename records for the upcoming season. This release adds the NDCs for the 2024/2025 season and associates these new NDCs to the trivalent CVX, CPT, and Product codes. All new NDCs are added once they have been published by the FDA in their drug listing and in DailyMed. All expected vaccine NDCs are included in this release, except FluMist which does not yet have NDCs published in the FDA files. The following new trivalent influenza vaccine NDCs have been added and associated to the CVX, MVX, and CPT codes. Please see the note following this table regarding a discrepancy in the FDA drug listing file for one of the Sanofi products.
CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Sale NDC11 | Sale NDC10 | Use NDC11 | Use NDC10 | Presentation | CPT Code | CPT Description |
|---|
140 | Influenza, split virus, trivalent, PF | FLUARIX | GlaxoSmithKline Biologicals SA | SKB | 58160-0884-52 | 58160-884-52 | 58160-0884-41 | 58160-884-41 | SYRINGE, 0.5mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
|---|
153 | Influenza, MDCK, trivalent, PF | Flucelvax | Seqirus Inc. | SEQ | 70461-0654-03 | 70461-654-03 | 70461-0654-04 | 70461-654-04 | SYRINGE, 0.5 mL | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
|---|
141 | Influenza, split virus, trivalent, preservative | Afluria | Seqirus PTY Lth. | SEQ | 33332-0124-10 | 33332-124-10 | 33332-0124-11 | 33332-124-11 | VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
|---|
90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use |
|---|
140 | Influenza, split virus, trivalent, PF | FLULAVAL | ID Biomedical Corporation of Quebec | IDB | 19515-0810-52 | 19515-810-52 | 19515-0810-41 | 19515-810-41 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
|---|
141 | Influenza, split virus, trivalent, preservative | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0641-15 | 49281-641-15 | 49281-0641-78 | 49281-641-78 | VIAL, 5 mL, MULTI-DOSE | 90658 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use |
|---|
90657 | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use |
|---|
140 | Influenza, split virus, trivalent, PF | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0424-50 | 49281-424-50 | 49281-0424-88 | 49281-424-88 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
|---|
155 | Influenza, recombinant, trivalent, PF | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0724-10 | 49281-724-10 | 49281-0724-88 | 49281-724-88 | SYRINGE, 0.5 mL | 90673 | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use |
|---|
135 | Influenza, high-dose, trivalent, PF | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | PMC | 49281-0124-65 | 49281-124-65 | 49281-0124-88 | 49281-124-88 | SYRINGE, 0.5 mL | 90662 | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use |
|---|
320 | Influenza, MDCK, trivalent, preservative | Flucelvax | Seqirus Inc. | SEQ | 70461-0554-10 | 70461-554-10 | 70461-0554-11 | 70461-554-11 | VIAL, 5 mL, MULTI-DOSE | 90661 | Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use |
|---|
140 | Influenza, split virus, trivalent, PF | Afluria | Seqirus PTY Lth. | SEQ | 33332-0024-03 | 33332-024-03 | 33332-0024-04 | 33332-024-04 | SYRINGE, 0.5 mL | 90656 | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use |
|---|
168 | Influenza, adjuvanted, trivalent, PF | FLUAD | Seqirus, Inc. | SEQ | 70461-0024-03 | 70461-024-03 | 70461-0024-04 | 70461-024-04 | SYRINGE, 0.5mL | 90653 | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use |
|---|
Note: FDA Drug Listing Discrepancy. Sanofi product NDCs (UoS NDC11 49281-641-15 and UoU 49281-641-78) are correctly listed in DailyMed as a 5 mL multi-dose vial. The FDA drug listing file has these NDCs incorrectly listed as a 0.5 mL single-dose vial. The information has been verified with Sanofi and a correction to the FDA listing is in process. This will not impact the files found on the CDC vaccine code set web site, but the incorrect FDA packaging fields (as well as the CDC’s correct packaging fields) are shown in Viewpoint and are included in the REST Web Services content model. CDC will update this information as soon as the FDA listing is corrected. - Retired Quadrivalent Influenza Vaccines for 2023/2024 Season
The following quadrivalent 2023/2024 influenza season vaccine NDC codes have been retired and replaced with new trivalent NDCs for the 2024/2025 season. All quadrivalent 2023/2024 vaccines have been retired except for the NDCs for FluMist which does not yet have new trivalent NDCs published in the FDA files. In addition to the addition of NDC end dates to signify retirement. Minor edits were made to the NDC Generic Descriptions for consistency.
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Sale NDC10 | Use NDC11 | Use NDC10 |
|---|
Afluria Quadrivalent | Seqirus PTY Lth. | 33332-0323-03 | 33332-323-03 | 33332-0323-04 | 33332-323-04 |
|---|
Afluria Quadrivalent | Seqirus PTY Lth. | 33332-0423-10 | 33332-423-10 | 33332-0423-11 | 33332-423-11 |
|---|
FLUAD QUADRIVALENT | Seqirus, Inc. | 70461-0123-03 | 70461-123-03 | 70461-0123-04 | 70461-123-04 |
|---|
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0909-52 | 58160-909-52 | 58160-0909-41 | 58160-909-41 |
|---|
Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0723-10 | 49281-723-10 | 49281-0723-88 | 49281-723-88 |
|---|
Flucelvax Quadrivalent | Seqirus Inc. | 70461-0323-03 | 70461-323-03 | 70461-0323-04 | 70461-323-04 |
|---|
Flucelvax Quadrivalent | Seqirus Inc. | 70461-0423-10 | 70461-423-10 | 70461-0423-11 | 70461-423-11 |
|---|
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0814-52 | 19515-814-52 | 19515-0814-41 | 19515-814-41 |
|---|
Fluzone High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0123-65 | 49281-123-65 | 49281-0123-88 | 49281-123-88 |
|---|
Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0423-50 | 49281-423-50 | 49281-0423-88 | 49281-423-88 |
|---|
Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0639-15 | 49281-639-15 | 49281-0639-78 | 49281-639-78 |
|---|
Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 49281-0639-15 | 49281-639-15 | 49281-0639-78 | 49281-639-78 |
|---|
3. Other Code Set Updates - New NDCs Added
The following new NDCs have been added:
CVX Code | CVX Short Description | Sale Proprietary Name | Sale Labeler | MVX Code | Sale NDC11 | Sale NDC10 | Use NDC11 | Use NDC10 | Presentation | CPT Code | CPT Description |
|---|
83 | Hep A, ped/adol, 2 dose | HAVRIX | A-S Medication Solutions | SKB | 50090-3781-00 | 50090-3781-0 | 50090-3781-01 | 50090-3781-1 | SYRINGE, 0.5 mL | 90633 | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use |
|---|
25 | typhoid, oral | Vivotif (*) | Bavarian Nordic A/S | BN | 50632-0016-02 | 50632-016-02 | 50632-0016-04 | 50632-016-04 | BLISTER PACK, 4 CAPSULE, COATED | 90690 | Typhoid vaccine, live, oral |
|---|
(*) Vivotif previous NDCs were manufactured by and assigned MVX code PAX. Vivotif now is manufactured by Bavarian Nordic (BN). A new Vivotif-BN product record has been added to associate the tradename to CVX 25 and MVX code BN. - Updated RABAVERT MVX Code and Product Tradename Crosswalk
The original assignment of MVX for the RABAVERT vaccine was for GlaxoSmithKline (MVX code SKB). GlaxoSmithKline (GSK) was the manufacturer and NDCs were produced that were manufactured by GSK but packaged as the labeler by Bavarian Nordic. On March 22, 2024, this changed in the FDA DailyMed SPL listing and Bavarian Nordic became both the manufacturer and the packager on the listed NDC labels. We did not pick this change up at that time. The following updates have been made in the vaccine code set: - The MVX code assigned to NDC11 50632-0010-01 has been updated to Bavarian Nordic (MXV code BN)
- The product tradename associations for RABAVERT which crosswalks RABAVERT to CVX 176 and to the MVX code have been updated as follows:
- The existing RABAVERT tradename record associated to CVX 176 and MVX SKB has been retired.
- A new tradename record has been added which associates RABAVERT to CVX 176 and to the MVX code for Bavarian Nordic.
- CPT to CVX Code Map Updates
The following mapping corrections have been made for CPT code 90675, “Rabies vaccine, for intramuscular use”: - Removed map to CVX 90, “rabies vaccine, unspecified formulation”.
- Added map to CVX 175, “Human Rabies vaccine from human diploid cell culture”.
- Add map to CVX 176, “Human rabies vaccine from Chicken fibroblast culture”.
- Other NDC Code Updates
The following NDC code updates represent retired codes or other modifications which have changed the date of last update.
Sale NDC11 | Sale Proprietary Name | Sale Labeler | Sale Start Date | Sale End Date | Use NDC11 | Use Start Date | Use End Date |
|---|
1. NDCs Retired – End Dates Added |
|---|
00069-2392-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 9/11/2023 | 6/30/2024 | 00069-2392-01 | | 6/30/2024 |
|---|
2. NDCs – Updated to reflect addition and population of new field “Vaccine Season”. |
|---|
4. New NDC Consolidated Crosswalk Table Added to CDC’s IIS Data Code Sets Website A new expanded NDC Crosswalk table has been introduced. This table consolidates more fields, codes, and information than the previous NDC Crosswalk Lookup table. The original table is still available in HTML on-line version as well as downloadable in flat file and Excel formats. The new table NDC Consolidated Crosswalk has many more columns and is only available as a downloadable flat file and in Excel format. The new NDC Consolidated Crosswalk table provides an important enhancement and information tool for users of the vaccine codes. It brings together NDC-related information and the associated vaccine codes for those NDCs. This will reduce the need for end users to have to link multiple separate report files in order to capture the information they need.
The NDC crosswalk tables only include codes associated to NDCs and their related CVX and other vaccine codes. The tables include both current and retired NDC codes and the historic code associations to these found in the content model. They do not include: - NDC codes intentionally excluded through curation, or CVX codes and associations that do not have any NDCs associated to them (e.g. unspecified CVX codes, non-US CVX codes).
- VIS associations to CVX are not included.
- CVX vaccine groups are not included.
The following fields appear on the new consolidated table. We have highlighted the changes and new fields as follows: - Fields highlighted in blue represent content that has been added and was not previously available on the original NDC crosswalk report. These fields were only available on other standard reports.
- Fields highlighted in yellow represent fields that are entirely new and were never included on any of the previously published structured reports. A brief description of these new fields is provided below.
- Fields that are not highlighted are those that appear on the original NDC Crosswalk Lookup table.
The fields highlighted are new fields that now exist on the new NDC Consolidated Crosswalk, but are fields that appear on other current outputs. Several new fields have been added that were not previously available on structured outputs except through a REST Web Service and Viewpoint access methods.
Sale NDC11 | Sale NDC10 | Sale Proprietary Name | Sale Labeler | SalePackForm | Route | Sale Start Date | Sale End Date | Sale GTIN | Sale Last Update |
|---|
Vaccine Season | Use NDC11 | Use NDC10 | UseUnitPackForm | Use Start Date | Use End Date | Use GTIN | Use Last Update |
|---|
CVX Code | CVX Short Description | CVX Long Description | CVX Status | CVX Effective Date | CVX Retired Date |
|---|
MVX Code | MVX Manufacturer | MVX Status | CPT | CPT Short Description | CPT Long Description | CPT Status |
|---|
A brief overview of the new (yellow) highlighted fields follows: - Vaccine Season. Seasonal vaccine NDCs have been populated with the vaccine season starting with the 2019/2020 season. The notation for regular influenza is shown as two years e.g. 2023/2024. If the vaccine is not a northern hemisphere influenza vaccine but is another type of seasonal vaccine, additional description is added e.g. “2020 (Southern Hemisphere)” or “COVID Fall 2023”
- CVX Effective Date. The CVX effective date represents the earliest date that a product that would be associated to this CVX code was available in the US market. The exact day may not be precise, the month and year should represent the product introduction. All new CVX codes associated to vaccines have been assigned dates starting in late 2017, we continue to research older CVX codes to identify the appropriate dates.
- CVX Retired Date. This date is only assigned when there is clarity that a product is no longer available or withdrawn from the market and no other product might be associated to this CVX.
- CPT Code. A new additional CPT map has been created. The CPT shown here is the CPT to which the specific NDC has been mapped. This is typically the same as the CPT identified in the CDC’s CPT to CVX map, but it allows more precision when there is a specific CPT for an NDC or dose. This new map has only been populated for active NDCs and active CPT codes. We will continue the mapping going forward but do not plan to map historic NDCs.
- CPT Short Description. This is the AMA’s abbreviated CPT description.
- CPT Long Description. This is the AMA’s long CPT description.
- CPT Status. This is a binary status of active/inactive. Inactive CPT codes are those that have been removed/deprecated from the published AMA files and thus should not be used for billing.
|
|---|
Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348
Questions or Problems | |
|---|
|
|---|
|
